Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 846
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 
This article has been cited by
1Risk factors for potential drug-drug interactions in intensive care unit patients
Slobodan M. Jankovic,Ana V. Pejcic,Miloš N. Milosavljevic,Valentina D. Opancina,Nikola V. Pešic,Tamara T. Nedeljkovic,Goran M. Babic
Journal of Critical Care.2018;43()1
[DOI]
2Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases
Bovornpat Suriyapakorn,Pun Chairat,Suwanan Boonyoprakarn,Pimonwan Rojanarattanangkul,Wassana Pisetcheep,Natthaphon Hunsakunachai,Pornpun Vivithanaporn,Supakit Wongwiwatthananukit,Phisit Khemawoot,Masaki Mogi
PLOS ONE.2019;14(11)e0225239
[DOI]
3Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases
D. Tomic,B. Pirkic,K. Skala,L. Kranjcevic
PLOS ONE.2019;14(11)375
[DOI]
4Potential drug-drug interactions in pediatric patients admitted to intensive care unit of Khyber Teaching Hospital, Peshawar, Pakistan: A cross-sectional study
Mohammad Ismail,Sana Aziz,Sidra Noor,Iqbal Haider,Faryal Shams,Inamul Haq,Faiza Khadim,Qasim Khan,Fahadullah Khan,Muhammad Asif
Journal of Critical Care.2017;40(11)243
[DOI]
5Prevalence of QT interval prolonging drug–drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study
Qasim Khan,Mohammad Ismail,Iqbal Haider,Fahadullah Khan
International Journal of Clinical Pharmacy.2017;39(6)1256
[DOI]
6Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?
Sidra Noor,Mohammad Ismail,Iqbal Haider,Faiza Khadim
Annals of Hepatology.2018;17(6)1001
[DOI]
7Safety of psychopharmacotherapy: a clinical and pharmacological approach
O. O. Kirilochev,A. R. Umerova
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2019;119(10)127
[DOI]
8Safety of psychopharmacotherapy: a clinical and pharmacological approach
Imran Nizamuddin,Raveena Basra,Sai Vanam,Nurbanu Pirani
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2019;119(10)156
[DOI]
9Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes
Alexander V. Dmitriev,Alexey A. Lagunin,Dmitry ?. Karasev,Anastasia V. Rudik,Pavel V. Pogodin,Dmitry A. Filimonov,Vladimir V. Poroikov
Current Topics in Medicinal Chemistry.2019;19(5)319
[DOI]
10A comparison of potential psychiatric drug interactions from six drug interaction database programs
Scott Monteith,Tasha Glenn
Psychiatry Research.2019;275(5)366
[DOI]
11Therapeutisches Drug-Monitoring (TDM) in der Praxis
Andreas von Heydwolff
psychopraxis. neuropraxis.2018;275(5)366
[DOI]
12E-Health und die Realität – was sehen wir heute schon in der Klinik?
H. Gehring,K. Rackebrandt,M. Imhoff
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.2018;61(3)252
[DOI]
13Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
Martin Klietz,Stephan Greten,Florian Wegner,Günter U. Höglinger
Drugs & Aging.2019;36(6)511
[DOI]
14Prevalence of potential drug–drug interactions in outpatients on treatment with parenteral antineoplastic drugs
M. Castro-Manzanares,F. do Pazo-Oubiña,R. M. Rodríguez-Rincón
International Journal of Clinical Pharmacy.2019;36(6)511
[DOI]
15The prevalence and severity of potential drug- drug interactions among polypharmacy patients in Jordan
Mohammad B. Nusair,Sayer I. Al-azzam,Rasha. M. Arabyat,Haneen A. Amawi,Karem H. Alzoubi,Asma Rabah
Saudi Pharmaceutical Journal.2019;36(6)511
[DOI]
16Yogun Bakim Hastalarinda Antibiyotiklerin Diger Ilaçlarla Etkilesimlerinin Degerlendirilmesi
EMRE KARA,Kamer Tecen-Yücel,Nesligül Özdemir,Ahmet Çagkan Inkaya,Aygin Bayraktar-Ekincioglu,Kutay Demirkan,Serhat Ünal
STED / Sürekli Tip Egitimi Dergisi.2019;36(6)404
[DOI]
17Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort
Guillaume Beinse,Delphine Reitter,Lauriane Segaux,Muriel Carvahlo-Verlinde,Benoit Rousseau,Christophe Tournigand,Tristan Cudennec,Marie Laurent,Pascaline Boudou-Rouquette,Elena Paillaud,Florence Canouï-Poitrine,Philippe Caillet
Journal of Geriatric Oncology.2019;36(6)404
[DOI]
18Clozapine Patients at the Interface between Primary and Secondary Care
Marita Barrett,Anna Keating,Deirdre Lynch,Geraldine Scanlon,Mary Kigathi,Fidelma Corcoran,Laura Sahm
Pharmacy.2018;6(1)19
[DOI]
19Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro
Leibin Shen,Jun Wang,Yongdong Yi,Chenmin Ye,Rongrong Wang,Guojun Xia,Chengyang Yu,Fuyang Tu,Jingxuan Xu,Zhiqiang Zheng
Drug Testing and Analysis.2019;11(4)595
[DOI]
20A Cross-Sectional Study on Single-Day Use of Proton Pump Inhibitors in Tertiary Care Hospitals of South India
Zabiuddin Ahad M,Alekhya Lavu,Maria Ansari,Raviraj Acharya V,Rajesh Vilakkathala
Hospital Pharmacy.2019;11(4)001857871987387
[DOI]
21Prevalence and trend of potential drug–drug interaction among children with depression in U.S. outpatient settings
L. Leanne Lai,Goar Alvarez,Linh Dang,Dung Vuong,Vy Ngo,Yailin Jo,Leroy Koh
Journal of Pharmaceutical Health Services Research.2019;10(4)393
[DOI]
Feedback

Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal